\begin{table*}[]
\renewcommand{\arraystretch}{1.0}
\centering
\small
\caption{The overall results of different SOTA methods on 6 SER corpora. Evaluation measures are UAR(\%) / WAR(\%). The `-' implies the lack of this measure. Furthermore, the superscripts indicate different evaluation settings. The `$^{*}$' implies a 10-fold cross-validation with 90\% and 10\% samples in train and test sets respectively, whose model is only evaluated at the last epoch. The `$^{**}$' implies a 10-fold cross-validation that 90\% of samples are used for training and 10\% for both validating and testing. Note that methods without superscript means that there is no source code to verify their specific experimental details.}

\begin{tabular*}{1\linewidth}{@{\extracolsep{\fill}}lcc|lcc|lcc}
\toprule[1.5pt]
\textbf{Model}    & \textbf{Year}     & \textbf{CASIA}         & \textbf{Model}   & \textbf{Year}      & \textbf{EMODB}         & \textbf{Model}   & \textbf{Year}      & \textbf{EMOVO}         \\
\midrule
DT-SVM~\cite{DT_SVM}  & 2019     & 85.08 / 85.08          & TSP+INCA~\cite{TSP_INCA} & 2021       & 89.47 / 90.09           & RM+CNN~\cite{RM_CNN} & 2021       & 68.93 / 68.93            \\
TLFMRF~\cite{TLFMRF} & 2020        & 85.83 / 85.83           & GM-TCN$^{**}$~\cite{GM_TCNet} & 2022       & 90.48 / 91.39            & SVM~\cite{MFMC_SVM} & 2021        & 73.30 / 73.30          \\
GM-TCN$^{**}$~\cite{GM_TCNet} & 2022       & 90.17 / 90.17          &  LightSER$^{**}$~\cite{IEMOCAP_CNN2}   & 2022    & 94.15 / 94.21        & TSP+INCA~\cite{TSP_INCA} & 2021       & 79.08 / 79.08           \\
CPAC$^{**}$~\cite{CPAC_IJCAI}  & 2022        & 92.75 / 92.75           & CPAC$^{**}$~\cite{CPAC_IJCAI}  & 2022         & 94.22 / 94.95          & CPAC$^{**}$~\cite{CPAC_IJCAI}  & 2022       & 85.40 / 85.40           \\\midrule
\textbf{\methodname}$^{*}$ & 2023 & \textbf{91.08 / 91.08}&
\textbf{\methodname}$^{*}$ & 2023 & \textbf{89.19 / 90.28}&
\textbf{\methodname}$^{*}$ & 2023 & \textbf{86.56 / 86.56}\\
\textbf{\methodname}$^{**}$ & 2023 & 94.67 / 94.67& 
\textbf{\methodname}$^{**}$ & 2023 & 95.17 / 95.70&
\textbf{\methodname}$^{**}$ & 2023 & 92.00 / 92.00

\\\midrule\midrule
\textbf{Model}   & \textbf{Year}      & \textbf{IEMOCAP}         & \textbf{Model}    & \textbf{Year}     & \textbf{RAVDESS}       & \textbf{Model}    & \textbf{Year}     & \textbf{SAVEE}     \\
\midrule
MHA+DRN~\cite{IEMOCAP_DRN}  & 2019     & 67.40 / ~~~~-~~~~            & CNN+INCA~\cite{INCA_CNN} & 2021        & ~~~~-~~~~ / 85.00          & DCNN~\cite{DCNN} & 2020       & ~~~~-~~~~ / 82.10           \\
CNN+Bi-GRU~\cite{IEMOCAP_GRU}  & 2020     & 71.72 / 70.39          & TSP+INCA~\cite{TSP_INCA} & 2021        & 87.43 / 87.43           &    TSP+INCA~\cite{TSP_INCA} & 2021        & 83.38 / 84.79         \\
SPU+MSCNN~\cite{IEMOCAP_CNN1} & 2021   & 68.40 / 66.60             & GM-TCN$^{**}$~\cite{GM_TCNet} & 2022       & 87.64 / 87.35           &     CPAC$^{**}$~\cite{CPAC_IJCAI}  & 2022         & 83.69 / 85.63           \\
LightSER$^{**}$~\cite{IEMOCAP_CNN2}   & 2022    & 70.76 / 70.23           & CPAC$^{**}$~\cite{CPAC_IJCAI}  & 2022         & 88.41 / 89.03          & GM-TCN$^{**}$~\cite{GM_TCNet} & 2022       & 83.88 / 86.02        \\\midrule
\textbf{\methodname}$^{*}$ & 2023 & \textbf{69.00 / 68.29}&
\textbf{\methodname}$^{*}$ & 2023 & \textbf{90.04 / 90.07}&
\textbf{\methodname}$^{*}$ & 2023 & \textbf{77.26 / 79.36}\\
\textbf{\methodname}$^{**}$ & 2023 & 72.50 / 71.65&
\textbf{\methodname}$^{**}$ & 2023 & 91.93 / 92.08&
\textbf{\methodname}$^{**}$ & 2023 & 86.07 / 87.71\\\bottomrule[1.5pt]

\end{tabular*}
\label{tab:SOTA}
\end{table*}

